Cullinan Therapeutics Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer, reported its fourth-quarter 2025 financial results. The company reported a loss of $7.73 per share on its preferred stock for the quarter.
The company is advancing multiple clinical programs, including zipalertinib, a small molecule in Phase 3 trials for non-small cell lung cancer, CLN-978, a T cell engager for systemic lupus erythematosus and rheumatoid arthritis, and CLN-619, a monoclonal antibody in Phase 1 trials for solid tumors and multiple myeloma.
A detailed analysis of Cullinan Therapeutics Inc’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings first appeared on Alphastreet.
